Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
作者信息
Chatwal Monica S, Tanvetyanon Tawee
机构信息
Division of Medicine, Division of Hematology/Oncology, University of South Florida/H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Division of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
出版信息
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S208-S210. doi: 10.21037/tlcr.2018.07.15.
Abstract
摘要
相似文献
1
Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?转移性非小细胞肺癌的联合化疗与免疫治疗：个性化医疗的挫折？
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S208-S210. doi: 10.21037/tlcr.2018.07.15.
2
Personalized chemotherapy of lung cancer: What the radiologist should know.肺癌的个体化化疗：放射科医生应该知道什么。
Diagn Interv Imaging. 2016 Mar;97(3):287-96. doi: 10.1016/j.diii.2015.11.013. Epub 2016 Feb 5.
3
Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer.冷冻治疗、化疗与 DC-CIK 免疫治疗联合应用于转移性非小细胞肺癌治疗的疗效观察。
Cryobiology. 2013 Oct;67(2):235-40. doi: 10.1016/j.cryobiol.2013.08.001. Epub 2013 Aug 13.
4
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
5
Chemotherapy remains an essential element of personalized care for persons with lung cancers.化疗仍然是肺癌患者个性化治疗的重要组成部分。
Ann Oncol. 2016 Oct;27(10):1829-35. doi: 10.1093/annonc/mdw271. Epub 2016 Jul 25.
6
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.血管生成抑制剂在免疫检查点抑制剂和靶向治疗时代的转移性非小细胞肺癌中的作用。
Curr Treat Options Oncol. 2019 Feb 18;20(3):21. doi: 10.1007/s11864-019-0617-6.
7
Management of non-small cell lung cancer in the era of personalized medicine.个性化医疗时代的非小细胞肺癌管理
Int J Biochem Cell Biol. 2016 Sep;78:173-179. doi: 10.1016/j.biocel.2016.07.011. Epub 2016 Jul 15.
8
Modeling of Combination Chemotherapy and Immunotherapy for Lung Cancer.肺癌联合化疗与免疫治疗的建模
Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:273-276. doi: 10.1109/EMBC.2019.8857566.
9
Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy.外科肿瘤衍生的个性化光热疫苗制剂用于癌症免疫治疗。
ACS Nano. 2019 Mar 26;13(3):2956-2968. doi: 10.1021/acsnano.8b07371. Epub 2019 Mar 4.
10
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective.非小细胞肺癌中的个性化医疗：从药物基因组学角度的综述
Acta Pharm Sin B. 2018 Jul;8(4):530-538. doi: 10.1016/j.apsb.2018.04.005. Epub 2018 Apr 30.
引用本文的文献
1
Resistance to chemoimmunotherapy in non-small-cell lung cancer.非小细胞肺癌对化疗免疫疗法的耐药性。
Cancer Drug Resist. 2020 Jul 12;3(3):445-453. doi: 10.20517/cdr.2020.09. eCollection 2020.
2
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.新辅助 PD-1 抑制剂（信迪利单抗）联合化疗（白蛋白紫杉醇联合卡铂）治疗可切除 IIIA/IIIB 期非小细胞肺癌的疗效和安全性的初步分析：一项单臂、Ⅱ期临床试验。
J Cancer Res Clin Oncol. 2023 Feb;149(2):819-831. doi: 10.1007/s00432-021-03896-w. Epub 2022 Feb 22.
3
Cotargeting of miR-126-3p and miR-221-3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling.靶向 miR-126-3p 和 miR-221-3p 抑制 PIK3R2 和 PTEN，通过阻断 AKT 和 CXCR4 信号通路抑制肺癌生长和转移。
Mol Oncol. 2021 Nov;15(11):2969-2988. doi: 10.1002/1878-0261.13036. Epub 2021 Jul 21.
4
A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.一种新型 CXCR4 拮抗剂可拮抗顺铂诱导的肺癌中转移性龛的矛盾生成。
Mol Ther. 2021 Oct 6;29(10):2963-2978. doi: 10.1016/j.ymthe.2021.05.014. Epub 2021 May 21.
5
A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient.一名非小细胞肺癌患者对新辅助化疗和免疫治疗的病理完全缓解。
Transl Lung Cancer Res. 2020 Oct;9(5):2157-2160. doi: 10.21037/tlcr-20-770.
6
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.CXCR4 抑制作用可逆转转移性 NSCLC 干细胞的免疫抑制特性。
Front Immunol. 2020 Oct 2;11:02168. doi: 10.3389/fimmu.2020.02168. eCollection 2020.
本文引用的文献
1
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
2
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
3
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
4
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
5
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
Zotero 插件